계명대학교 의학도서관 Repository

A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis

Metadata Downloads
Author(s)
Suk-Won AhnIn Soo JooByung-Jo KimJung-Joon SungSa-Yoon KangJeeyoung OhYang-Ki MinnBum Chun SuhSun-Young OhYoon-Ho HongTai-Seung NamJung Im SeokYoung-Eun ParkHa Young ShinEun Bin ChoJe-Young ShinHung Youl SeokJin-Sung ParkByoung-Joon Kim
Keimyung Author(s)
Seok, Hung Youl
Department
Dept. of Neurology (신경과학)
Journal Title
Journal of Neurological Sciences
Issued Date
2017
Volume
379
Keyword
Myasthenia gravisMGTacrolimusPrednisoloneMGCSADR
Abstract
Introduction:
Several clinical studies using tacrolimus revealed reasonable therapeutic mechanisms and efficacy in patients with myasthenia gravis (MG). However, long-period studies in a large number of patients with MG are limited; therefore, the aim of this study was to investigate the therapeutic efficacies and safety of tacrolimus in patients with MG during a 12-month follow-up period.
Methods:
Tacrolimus was administered to 150 patients with MG who were recruited based on the inclusion criteria. Fifteen medical centers in Korea participated in this study. The efficacy of tacrolimus was assessed using MG composite scales (MGCS) and the prednisolone-sparing effect. And the adverse drug reactions (ADRs) of tacrolimus were monitored in each patient from the beginning of tacrolimus treatment to the end of the follow-up period.
Results:
After starting tacrolimus, the 32 patients were affected by ADRs, and consequentially 134 patients of the enrolled patients were followed up for 12 months. They showed that the mean prednisolone dosage significantly decreased (6.1 ± 7.6 mg/day), compared to that in the baseline (11.3 ± 9.5 mg/day), and MGCS significantly improved after 12 months of tacrolimus treatment, compared to that at the baseline.
Conclusions:
Our study showed that tacrolimus would be an effective immunosuppressant as an initial therapeutic agent in patients with MG; in addition, it showed tolerable safety profiles during the 12-month follow-up evaluation.
Keimyung Author(s)(Kor)
석흥열
Publisher
School of Medicine (의과대학)
Citation
Suk-Won Ahn et al. (2017). A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis. Journal of Neurological Sciences, 379, 271–275. doi: 10.1016/j.jns.2017.05.060
Type
Article
ISSN
0022-510X
Source
https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(17)30367-2
DOI
10.1016/j.jns.2017.05.060
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41034
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Neurology (신경과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.